DelveInsight’s ‘Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the Progressive Fibrosing Interstitial Lung Disease, historical and forecasted epidemiology as well as the Progressive Fibrosing Interstitial Lung Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Progressive Fibrosing Interstitial Lung Disease market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Progressive Fibrosing Interstitial Lung Disease market size from 2019 to 2032. The Report also covers current Progressive Fibrosing Interstitial Lung Disease treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Some of the key facts of the Progressive Fibrosing Interstitial Lung Disease Report:
Key benefits of the Indication Market report:
Got queries? Click here to learn more about Progressive Fibrosing Interstitial Lung Disease Insights
Progressive fibrosing interstitial lung diseases Overview
Progressive fibrosing interstitial lung diseases (PF-ILD) consist of a diverse group of interstitial lung diseases (ILD) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation, and earlier mortality.
Interstitial lung disease is believed to be caused by long-term exposure to hazardous materials, such as asbestos or coal dust, or it can be caused by an auto-immune disease such as rheumatoid arthritis. Once lung scarring occurs, it is generally irreversible.
Treatment for ILDs varies depending on the type of ILD diagnosed and the severity. Lung damage from ILDs is often irreversible and progressive, so treatment normally centers on relieving symptoms, improving quality of life, and slowing the disease’s progression. Medications, such as corticosteroids, can be used to decrease inflammation in the lungs.
Nintedanib (Ofev) is the only approved drug in the PF-ILD treatment landscape. Along with Ofev the current market is mainly attributed to corticosteroids and immunosuppressants for treatment. Novel uses of antifibrotic therapies are emerging due to a paucity of evidence-based treatments for multiple ILD subtypes. The market is anticipated to expect launch of several emerging therapies in PF- ILD treatment domain in the forecast period.
Progressive fibrosing interstitial lung diseases Epidemiological Insights:
Progressive fibrosing interstitial lung diseases Epidemiological Segmentation
Progressive Fibrosing Interstitial Lung Disease Outlook
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) consist of a diverse group of interstitial lung diseases (ILDs) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation, and earlier mortality.
ILD and its progressing forms form a substantial proportion of disabling chronic lung diseases leading to significant morbidity and mortality. From the current treatment market scenario, Nintedanib is the only approved treatment in the chronic fibrotic ILDs in the 7MM. Myriads of patients with PF-ILDs are currently orphan of evidence-based treatments and are left with options of receiving corticosteroids and/or off-label immunosuppressive therapies with variable outcomes which are the mainstay of treatment in PF-ILDs. These unmet treatment gaps accentuate the launch of emerging therapies.
In the upcoming treatment landscape, there are a plethora of companies investigating agents for use in the PF-ILD and IPF-specific PF-ILD which includes Boehringer Ingelheim, Bristol-Myers Squibb, FibroGen, Hoffmann-La Roche Ltd., Pliant Therapeutics, Inc., United Therapeutics, Vicore Pharma AB. There are many more pharma companies that are conducting clinical trials for therapies of PF-ILD and IPF-specific PF-ILD.
Learn more by requesting for sample @ Progressive Fibrosing Interstitial Lung Disease Landscape
Progressive fibrosing interstitial lung diseases Key Companies
Progressive fibrosing interstitial lung diseases Therapies
Market Drivers
Market Barriers
Table of Contents
Click here to read more about Progressive fibrosing interstitial lung diseases Market Insights
Media ContactCompany Name: DelveInsight Business ResearchContact Person: Adya KaulEmail: Send EmailPhone: +91 9568243403Address:304 S. Jones Blvd #2432, Las Vegas NV City: Las VegasState: United StatesCountry: United StatesWebsite: https://www.delveinsight.com